The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Emelin A.Iu.

kafedra nervnykh bolezneĭ Voenno-meditsinskoĭ akademii, Sankt-Peterburg

Lobzin V.Iu.

Kafedra nervnykh bolezneĭ i kafedra psikhiatrii Voenno-meditsinskoĭ akademii, Sankt-Peterburg

Complex diagnostic of cognitive impairment

Authors:

Emelin A.Iu., Lobzin V.Iu.

More about the authors

Read: 5409 times


To cite this article:

Emelin AIu, Lobzin VIu. Complex diagnostic of cognitive impairment. S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(6‑2):33‑40. (In Russ.)
https://doi.org/10.17116/jnevro20171176233-40

Recommended articles:
Neuroimaging predictors of hemo­rrhagic transformation of ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12-2):34-38
Cognitive impairment in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):81-90
Como­rbidity of depression and deme­ntia: epidemiological, biological and therapeutic aspe­cts. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):113-121
Differentiated approach to cognitive reha­bilitation of patients after stroke. Problems of Balneology, Physiotherapy and Exercise Therapy. 2024;(6):5-11
Cognitive impairment in bili­nguals with neurological diseases. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):26-29
Modern aspe­cts of chro­nic cere­bral ischemia pathogenetic therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):106-113
Non-invasive biomarkers for early diagnosis of Alzheimer’s disease in bodily fluids. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):8-16

References:

  1. Dementia. Fact sheet N°362. March 2015. Accessed July 21, 2015. Available at: http://www.who.int/mediacentre/factsheets/fs362/en/
  2. Emelin AYu. Cognitive impairments in cerebrovascular disease: What is between health and dementia? Neurology, Neuropsychiatry, Psychosomatics. 2015;7(1):94-98. (In Russ.). https://doi.org/10.14412/2074-2711-2015-1-94-98
  3. Emelin AYu. New criteria for diagnosing Alzheimer’s disease. Neurology, Neuropsychiatry, Psychosomatics. 2011;3(4):5-8. (In Russ.). https://doi.org/10.14412/2074-2711-2011-337
  4. Davis D, Schmitt F, Wekstein D, Markesbery W. Alzheimer Neuropathologic Alterations in Aged Cognitively Normal Subjects. Journal of Neuropathology and Experimental Neurology. 1999;58(4):376-388. https://doi.org/10.1097/00005072-199904000-00008
  5. Bennett D, Schneider J, Arvanitakis Z, Kelly J, Aggarwal N, Shah R, Wilson R. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology. 2006;66(12):1837-1844. https://doi.org/10.1212/01.wnl.0000219668.47116.e6
  6. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR Jr, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):280-292. https://doi.org/10.1016/j.jalz.2011.03.003
  7. Jack CR Jr, Albert MS, Knopman DS, McKhann GM, Sperling RA, Carrillo MC, Thies B, Phelps CH. Introduction to the recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):257-262. https://doi.org/10.1016/j.jalz.2011.03.004
  8. Dubois B, Gauthier S, Cummings J. The utility of the new research diagnostic criteria for Alzheimer’s disease. Int Psychogeriatr. 2012;25(02): 175-177. https://doi.org/10.1017/s1041610212002098
  9. Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, Delacourte A, Frisoni G, Fox NC, Galasko D, Gauthier S, Hampel H, Jicha GA, Meguro K, O’Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Sarazin M, de Souza LC, Stern Y, Visser PJ, Scheltens P. Revising the definition of Alzheimer’s disease: a new lexicon. Lancet Neurol. 2010;9(11):1118-1127. https://doi.org/10.1016/S1474-4422(10)70223-4
  10. Illarioshkin SN. Mild cognitive impairment in neurological practice. Consilium medicum. Nevrologiya y revmatologiya. 2014;01:17-21. (In Russ.).
  11. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):270-279. https://doi.org/10.1016/j.jalz.2011.03.008
  12. Petersen RC, Roberts RO, Knopman DS, Boeve BF, Geda YE, Ivnik RJ, Smith GE, Jack CR Mild Cognitive Impairment: Ten Years Later. Archives of neurology. 2009;66(12):1447-1455. https://doi.org/10.1001/archneurol.2009.266
  13. Yakhno NN, Lokshina AB, Zakharov VV. Legkie y umerenniye cognitivniye rasstroistva. Clinicheskaya gerontologiya. 2005;11(9):38-39. (In Russ.).
  14. Jessen F, Amariglio RE, van Boxtel M, Breteler M, Ceccaldi M, Chételat G, Dubois B, Dufouil C, Ellis KA, van der Flier WM, Glodzik L, van Harten AC, de Leon MJ, McHugh P, Mielke MM, Molinuevo JL, Mosconi L, Osorio RS, Perrotin A, Petersen RC, Rabin LA, Rami L, Reisberg B, Rentz DM, Sachdev PS, de la Sayette V, Saykin AJ, Scheltens P, Shulman MB, Slavin MJ, Sperling RA, Stewart R, Uspenskaya O, Vellas B, Visser PJ, Wagner M; Subjective Cognitive Decline Initiative (SCD-I) Working Group.. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease. Alzheimers Dement. 2014;10(6):844-852. https://doi.org/10.1016/j.jalz.2014.01.001
  15. Levin OS. Diagnostika y lecheniye demencii v klinicheskoy praktike [book]. M. 2009. Accessed at January, 23 2017. Available at: https://shop.medspecial.ru/upload/iblock/323/3239f8c20e710c3c4a45947c4a4c5fcc.pdf (In Russ.).
  16. Lobzin VY. Comprehensive early diagnosis of cognitive impairment. Zh Nevrol Psikhiatr Im. S.S. Korsakova. 2015;115(11):72-79. (In Russ.). https://doi.org/10.17116/jnevro201511511172-79
  17. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nature Reviews Neurology. 2010;6(3):131-144. https://doi.org/10.1038/nrneurol.2010.4
  18. Hu W, Watts K, Shaw L, Howell JC, Trojanovski JQ, Basra S, Glass JD, Lah JJ, Levey AI. CSF beta-amyloid 1-42 — what are we measuring in Alzheimer’s disease? Annals of Clinical and Translational Neurology. 2014;2(2):131-139. https://doi.org/10.1002/acn3.160
  19. Lewczuk P, Mroczko B, Fagan A, Kornhuber J. Biomarkers of Alzheimer’s disease and mild cognitive impairment: A current perspective. Advances in Medical Sciences. 2015;60(1):76-82. https://doi.org/10.1016/j.advms.2014.11.002.
  20. Lobzin VYu, Emelin AYu, Odinak MM, Alekseeva LA, Monakhova NE. Value of determining the cerebrospinal fluid protein markers of amyloidosis and neurodegeneration in the diagnosis of vascular and neurodegenerative cognitive impairments. Neurology, neuropsychiatry, рsychosomatics. 2013;4:21-27. (In Russ.). https://doi.org/10.14412/2074-2711-2013-2450
  21. Odinak MM, Emelin AYu, Lobzin VYu, Vorobyev SV. Current capacities for neuroimaging in the differential diagnosis of cognitive impairments. Neurology, neuropsychiatry, рsychosomatics. 2012;4(2):51-55. (In Russ.). https://doi.org/10.14412/2074-2711-2012-2509
  22. Trufanov AG, Litvinenko IV, Rameshvili TE, Dovgopolaya KA, Voronkov LV. Dementia in Parkinson disease: role of brain cortex atrophic changes and magnetic resonance morphometry prognostic abilities. Vestn. Rossiiskoi Voenno-meditsinskoi akademii. 2012:39(3):116-122. (In Russ.).
  23. Voronkov LV, Trufanov AG, Fokin VA, Litvinenko IV, Odinak MM, Efimtsev AYu, Haimov DA, Bisaga GN. The possibilities of voxel-based morphometry in non-tumor brain diseases. Vestnin Rossiiskoi Voenno-meditsinskoi akademii. 2012;37(1):203-207. (In Russ.).
  24. Emelin AYu. Structural neuroimaging in the differential diagnostics of vascular cognitive impairment. Vestnik Rossiiskoi Voenno-meditsinskoi akademii. 2010;31(3): 97-102. (In Russ.).
  25. Emelin AYu, Odinak MM, Trufanov GE, Boikov IV, Vorob’ev SV, Kashin AV, Lobzin VYu, Kiselev VN, Rezvantsev MV. Positron-emission tomography possibilities in differential diagnostics of the dementias. Vestnik Rossiiskoi Voenno-meditsinskoi akademii. 2010;32(4):46-51. (In Russ.).
  26. Herholz K, Westwood S, Haense C, Dunn G. Evaluation of a Calibrated 18F-FDG PET Score as a Biomarker for Progression in Alzheimer Disease and Mild Cognitive Impairment. Journal of Nuclear Medicine. 2011;52(8): 1218-1226. https://doi.org/10.2967/jnumed.111.090902
  27. 11CPIB in a nondemented population: Potential antecedent marker of Alzheimer disease. Neurology. 2006;67(3):446-452. https://doi.org/10.1212/01.wnl.0000228230.26044.a4
  28. Bonte FJ, Weiner MF, Bigio EH, White CL 3rd. SPECT imaging in dementias. J Nucl Med. 2001;42(7):1131-1133.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.